Innoviva (INVA) Shares Outstanding (Weighted Average) (2009 - 2026)
Innoviva posted quarterly Shares Outstanding (Weighted Average) of $74.2 million for Q1 2026, up 18.26% year-on-year from $62.7 million in Q1 2025, and up 10.04% on a QoQ basis from $67.4 million in Q4 2025.
Innoviva (INVA) has 18 years of Shares Outstanding (Weighted Average) data on file, last reported at $74.2 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 18.26% year-over-year to $74.2 million; the trailing twelve-month figure through Mar 2026 stood at $74.2 million (up 18.26% YoY), and the FY2025 full-year result was $67.4 million, up 7.44% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $74.2 million, up from $67.4 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $74.2 million in Q1 2026 and bottomed at $62.6 million in Q3 2024.
- The 5-year median for Shares Outstanding (Weighted Average) is $65.4 million (2023), against an average of $66.3 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) slumped 31.39%; it then grew 18.26% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $69.6 million in 2022, then declined by 6.04% to $65.4 million in 2023, then decreased by 4.14% to $62.7 million in 2024, then increased by 7.44% to $67.4 million in 2025, then advanced by 10.04% to $74.2 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $74.2 million (Q1 2026), $67.4 million (Q4 2025), and $64.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 74.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.16 Mn |
| Dec 31, 2025 | 67.40 Mn |
| Sep 30, 2025 | 64.90 Mn |
| Jun 30, 2025 | 62.87 Mn |
| Mar 31, 2025 | 62.71 Mn |
| Dec 31, 2024 | 62.73 Mn |
| Sep 30, 2024 | 62.57 Mn |
| Jun 30, 2024 | 62.86 Mn |
| Mar 31, 2024 | 63.19 Mn |
| Dec 31, 2023 | 65.44 Mn |
| Sep 30, 2023 | 64.95 Mn |
| Jun 30, 2023 | 66.56 Mn |
| Mar 31, 2023 | 67.79 Mn |
| Dec 31, 2022 | 69.64 Mn |
| Sep 30, 2022 | 69.64 Mn |
| Jun 30, 2022 | 69.64 Mn |
| Mar 31, 2022 | 69.54 Mn |
| Dec 31, 2021 | 82.06 Mn |
| Sep 30, 2021 | 69.46 Mn |
| Jun 30, 2021 | 94.86 Mn |
| Mar 31, 2021 | 101.37 Mn |
| Dec 31, 2020 | 101.32 Mn |
| Sep 30, 2020 | 101.36 Mn |
| Jun 30, 2020 | 101.28 Mn |
| Mar 31, 2020 | 101.24 Mn |
| Dec 31, 2019 | 101.15 Mn |
| Sep 30, 2019 | 101.19 Mn |
| Jun 30, 2019 | 101.15 Mn |
| Mar 31, 2019 | 101.06 Mn |
| Dec 31, 2018 | 100.85 Mn |
| Sep 30, 2018 | 100.94 Mn |
| Jun 30, 2018 | 100.87 Mn |
| Mar 31, 2018 | 100.60 Mn |
| Dec 31, 2017 | 106.95 Mn |
| Sep 30, 2017 | 106.84 Mn |
| Jun 30, 2017 | 107.47 Mn |
| Mar 31, 2017 | 107.49 Mn |
| Dec 31, 2016 | 110.28 Mn |
| Sep 30, 2016 | 111.13 Mn |
| Jun 30, 2016 | 112.01 Mn |
| Mar 31, 2016 | 112.48 Mn |
| Dec 31, 2015 | 115.37 Mn |
| Sep 30, 2015 | 115.38 Mn |
| Jun 30, 2015 | 115.33 Mn |
| Mar 31, 2015 | 114.66 Mn |
| Dec 31, 2014 | 112.06 Mn |
| Sep 30, 2014 | 113.10 Mn |
| Jun 30, 2014 | 110.97 Mn |
| Mar 31, 2014 | 109.86 Mn |
| Dec 31, 2013 | 102.43 Mn |
| Sep 30, 2013 | 100.32 Mn |
| Jun 30, 2013 | 96.96 Mn |
| Mar 31, 2013 | 99.18 Mn |
| Dec 31, 2012 | 90.91 Mn |
| Sep 30, 2012 | 89.27 Mn |
| Jun 30, 2012 | 89.02 Mn |
| Mar 31, 2012 | 83.59 Mn |
| Dec 31, 2011 | 82.05 Mn |
| Sep 30, 2011 | 81.78 Mn |
| Jun 30, 2011 | 81.81 Mn |
| Mar 31, 2011 | 80.85 Mn |
| Dec 31, 2010 | 72.07 Mn |
| Sep 30, 2010 | 70.68 Mn |
| Jun 30, 2010 | 73.28 Mn |
| Dec 31, 2009 | 63.08 Mn |